10-Q: Nexalin Technology Reports First Quarter 2024 Results, Revenue Increases Driven by International Sales

Nexalin Technology's first quarter 2024 results show a significant increase in revenue driven by international device sales, alongside ongoing efforts to gain regulatory approvals for their neurostimulation devices.

Summary

• Nexalin Technology reported a net loss of $1.04 million for the first quarter of 2024, compared to a net loss of $0.75 million for the same period in 2023.
• The company's revenue increased to $78,671 in Q1 2024 from $30,560 in Q1 2023, primarily due to device sales to an overseas customer.
• Operating expenses totaled $1.14 million in Q1 2024, up from $0.80 million in Q1 2023, due to increased professional fees, salaries, and research and development costs.
• The company's gross profit margin improved to 88% in Q1 2024 from 77% in Q1 2023 due to a shift towards higher-margin device sales.
• Nexalin is focusing on obtaining regulatory approvals for its Gen-2 and Gen-3 neurostimulation devices, with clinical trials planned for the latter half of 2024.
• The company has a joint venture in China for the marketing and sale of its Gen-2 devices, which contributed $5,783 in equity method investment income in Q1 2024.
• Nexalin's cash and cash equivalents were $546,255 and short-term investments were $1,597,687 as of March 31, 2024.
• The company has a significant accumulated deficit of $78.1 million and expects to continue incurring operating losses and negative cash flows.
• There is substantial doubt about the company's ability to continue as a going concern within one year.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there is positive revenue growth and progress with regulatory approvals, the significant losses, going concern warning, and material weaknesses in internal controls raise serious concerns about the company's financial health and future prospects.

Positives

• The company experienced a significant increase in revenue, primarily due to international device sales.
• Gross profit margin improved due to a shift towards higher-margin device sales.
• The company is making progress with the FDA on regulatory approvals for its Gen-3 device.
• The joint venture in China is generating income for the company.
• The company has a working capital surplus of approximately $2.1 million.

Negatives

• The company continues to incur significant operating losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a significant accumulated deficit of approximately $78.1 million.
• The company's operating activities consume most of its cash resources.
• The company's disclosure controls and procedures were not effective as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on generating revenue from the joint venture, obtaining U.S. regulatory approvals, and raising additional capital.
• The company faces risks related to the Chinese economy, legal system, and government policies.
• The company may experience difficulty enforcing its intellectual property rights in China.
• The company's future success depends on the successful development and commercialization of its Gen-3 device.
• The company's ability to obtain regulatory approvals is uncertain.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S. and China beginning in the late second or early third quarter of 2024, and is also developing a new PMA application for the treatment of depression. The company expects to continue to incur operating losses and negative cash flows.

Management Comments

• The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3 devices can penetrate deeper into the brain and stimulate associated structures of mental illness.
• The Nexalin regulatory team has made a strategic decision to develop strategies for pilot trials and/or pivotal trials in various mental health disease states.
• Management does not believe we have sufficient cash for the next twelve months from the issuance of the financial statements.

Industry Context

The company is operating in the neurostimulation market, which is experiencing growth due to the increasing prevalence of mental health disorders. The company is attempting to differentiate itself through its proprietary waveform technology and virtual clinic model.

Comparison to Industry Standards

• Nexalin's focus on non-invasive neurostimulation aligns with a growing trend in the mental health treatment industry, where companies like NeuroMetrix and Neuronetics are also developing non-pharmacological treatments.
• The company's approach to virtual clinics is similar to that of companies like Talkspace and Teladoc, which are leveraging technology to improve access to mental health care.
• Nexalin's reliance on a joint venture for international expansion is a common strategy, but the risks associated with operating in China are significant and should be compared to other companies with similar operations.
• The company's financial results, particularly the significant accumulated deficit and negative cash flows, are not uncommon for early-stage medical device companies, but the going concern warning is a significant concern.
• The company's gross profit margin of 88% is relatively high, which is typical for medical device companies with proprietary technology.

Management Changes

Legal Proceedings

• The company is involved in a lawsuit filed by Sarah Veltz, alleging unpaid wages and sexual harassment.
• The company is engaged in settlement discussions with the Employment Development Department (EDD) of the State of California regarding the classification of certain workers.

Related Party Transactions

• The company has a consulting agreement with U.S. Asian Consulting Group, LLC, whose members are shareholders in the company.
• The company has a sublease agreement with IIcom Strategic Inc., controlled by the company's Chief Executive Officer.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be affected by delays in product development or regulatory approvals.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S. and China beginning in the late second or early third quarter of 2024.
• The company is developing a new PMA application for the treatment of depression.
• The company intends to implement new financial accounting controls and processes to address material weaknesses.

Key Dates

Keywords

neurostimulation, mental health, FDA, regulatory approval, joint venture, China, anxiety, insomnia, clinical trials, medical device, Gen-2, Gen-3, waveform, tele-health